Jump Financial LLC Has $923,000 Stock Holdings in Veru Inc. (NASDAQ:VERU)

Jump Financial LLC boosted its holdings in shares of Veru Inc. (NASDAQ:VERU) by 47.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 114,400 shares of the company’s stock after buying an additional 37,000 shares during the quarter. Jump Financial LLC owned about 0.14% of Veru worth $923,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of VERU. RMR Wealth Builders increased its position in Veru by 877.6% during the first quarter. RMR Wealth Builders now owns 2,395 shares of the company’s stock worth $26,000 after buying an additional 2,150 shares during the last quarter. Altshuler Shaham Ltd acquired a new position in Veru during the first quarter worth $34,000. O Shaughnessy Asset Management LLC increased its position in Veru by 1,877.1% during the first quarter. O Shaughnessy Asset Management LLC now owns 3,974 shares of the company’s stock worth $43,000 after buying an additional 3,773 shares during the last quarter. Captrust Financial Advisors acquired a new position in Veru during the first quarter worth $43,000. Finally, Legal & General Group Plc increased its position in Veru by 46.8% during the second quarter. Legal & General Group Plc now owns 8,959 shares of the company’s stock worth $72,000 after buying an additional 2,855 shares during the last quarter. 30.61% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Veru in a report on Tuesday, September 21st. TheStreet upgraded shares of Veru from a “d+” rating to a “c” rating in a report on Friday, September 17th. Brookline Capital Management restated a “buy” rating on shares of Veru in a report on Friday, August 27th. Oppenheimer restated a “buy” rating and set a $26.00 price target on shares of Veru in a report on Friday, August 27th. Finally, Zacks Investment Research cut shares of Veru from a “hold” rating to a “sell” rating in a report on Wednesday, August 11th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $17.46.

NASDAQ VERU opened at $8.80 on Thursday. The firm has a 50-day simple moving average of $8.40 and a 200 day simple moving average of $8.46. Veru Inc. has a twelve month low of $2.30 and a twelve month high of $24.57. The stock has a market cap of $702.72 million, a PE ratio of -879.12 and a beta of 0.63.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Thursday, August 12th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The firm had revenue of $17.66 million during the quarter, compared to analysts’ expectations of $13.98 million. Veru had a negative net margin of 0.25% and a negative return on equity of 7.62%. On average, sell-side analysts predict that Veru Inc. will post -0.19 earnings per share for the current year.

In other Veru news, Director Lucy Lu purchased 4,800 shares of the business’s stock in a transaction on Tuesday, August 17th. The stock was purchased at an average price of $6.78 per share, for a total transaction of $32,544.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 24.60% of the stock is owned by company insiders.

Veru Profile

Veru, Inc is an oncology biopharmaceutical company engaged in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.

Featured Story: What moving averages are used to define a golden cross?

Institutional Ownership by Quarter for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.